Clinical Trial

A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-11-13; most recent amendment 2026-04-14.
Status change: Not Yet Recruiting → Recruiting 2026-01-10
Trial Details
NCT Number NCT07229313
Lead Sponsor Kivu Bioscience Inc.
Conditions Advance Solid Tumors
Enrollment 76 participants
Start Date 2025-11-13
Primary Completion 2028-03-31 (estimated)
Study Completion 2030-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-16